drugset
drugset / Trial / NCT06025396

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

NCT06025396 ↗

Phase 1 Completed 30 enrolled Tempero Bio, Inc. National Institute on Drug Abuse (NIDA) · collab
RandomizedSequentialDouble-blindTreatment

Summary

A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.

Timeline

Start
2023-01-06
Primary completion
2023-12-22
Completion
2024-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject TMP-301 Unknown 25 mg —
Subject TMP-301 Unknown 50 mg —

Indications

substance-related disorder